Advances in chronic intestinal failure management and therapies

Abstract

Purpose of review To summarize changes and recent advances in therapies for chronic intestinal failure (CIF). Recent findings In the last few years, the management of CIF has significantly improved through better prevention and treatment of catheter-related bloodstream infections (CRBSIs) and intestinal failure-associated liver disease (IFALD), as well as improved enteral autonomy by using small bowel growth factors in selected patients. This may have been reflected by a recent reduction in small bowel transplantations. Summary Although CIF management has become more established and effective, the long-term implications of parenteral nutrition still place substantial burden on patients such that further work is required to improve patients’ quality of life as well as continued efforts to reduce complications relating to CIF management.

A comparison of health‐related quality of life in chronic intestinal failure and end‐stage kidney disease: A cross‐sectional study

“…[17][18][19][20] Over the past decades, the management and survival of affected people have improved, mainly because of advances in the provision of HPS and the establishment of multidisciplinary specialized teams. 12,21 Despite recent advances in treatment and care, access to HPS varies between and within countries that generally provide specialized supportive and palliative care for chronic nonmalignant types of organ failure. This could be due to lack of reliable data on how accessibility and availability of treatment and care impacts patient outcomes and disease burden.…”

“…CIF is a rare, complex, and heterogenous condition, characterized by severe symptoms and a high degree of morbidity and mortality 17–20 . Over the past decades, the management and survival of affected people have improved, mainly because of advances in the provision of HPS and the establishment of multidisciplinary specialized teams 12,21 . Despite recent advances in treatment and care, access to HPS varies between and within countries that generally provide specialized supportive and palliative care for chronic nonmalignant types of organ failure.…”

Current Insights Regarding Intestinal Failure-Associated Liver Disease (IFALD): A Narrative Review

“… Type II: prolonged acute condition, in which patients are metabolically unstable and require multidisciplinary care lasting for week to months. Type III: chronic condition, in which can be reversible or irreversible; patients are metabolically stable and require long-term parenteral nutrition over months or years [ 2 , 3 ]. …”

“…Type III: chronic condition, in which can be reversible or irreversible; patients are metabolically stable and require long-term parenteral nutrition over months or years [ 2 , 3 ].…”